A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selection.
Shahraz A, Penney M, Candido J, Opoku-Ansah G, Neubauer M, Eyles J, Ojo O, Liu N, Luheshi NM, Phipps A, Vishwanathan K.
Shahraz A, et al. Among authors: penney m.
CPT Pharmacometrics Syst Pharmacol. 2024 Oct;13(10):1670-1681. doi: 10.1002/psp4.13204. Epub 2024 Jul 23.
CPT Pharmacometrics Syst Pharmacol. 2024.
PMID: 39041713
Free PMC article.